OricPharma logo
ORIC Pharmaceuticals Adds Richard Heyman, Ph.D., Former CEO of Aragon and Seragon, to its Board of Directors
ORIC Pharmaceuticals Adds Richard Heyman, Ph.D., Former CEO of Aragon and Seragon, to its Board of Directors
March 09, 2015
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Heyman, Ph.D. will be joining its Board of Directors. Dr. Heyman was most recently CEO of Seragon Pharmaceuticals and, prior to that, CEO of Aragon Pharmaceuticals.
“I’ve had the pleasure of working with Rich Heyman on Aragon and Seragon, and he was an excellent leader with a strong sense of efficient drug development,” said Peter Svennilson, ORIC’s acting chief executive officer, referring to his time as Board Chairman of Aragon Pharmaceuticals and Seragon Pharmaceuticals. “He is very familiar with the basic science and clinical setting for hormone-resistant cancers and that will prove all the more helpful in shaping the strategic path of ORIC. His operational experience will be an invaluable asset to the Company.”
“ORIC has established an exceptional team focused on its greater mission,” said Dr. Heyman. “It will be an exciting period of growth and exploration for the Company as it establishes its discovery platform and selects its clinical programs.”
Dr. Heyman is a biopharmaceutical executive with over 25 years in the industry. Most recently he served as CEO of Seragon Pharmaceuticals, a company focused on the development of drugs targeting hormone dependent cancers that was acquired by the Roche group. He was also co-founder and CEO of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson in 2013. Previously, he co-founded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases which was acquired by Exelixis in 2004. Prior to X-Ceptor, he was Vice President of Research at Ligand Pharmaceuticals, where he led the development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the Board of Directors for BIOCOM, Organovo Inc., The Jenna Druck Center, and is a member of the Therapeutic Advisory Board for aTyr Pharma.
About ORIC Pharmaceuticals
ORIC is a privately-held pharmaceutical company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to these drugs. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.
ORIC was founded by two world-class experts in oncology, Dr. Charles Sawyers and Dr. Scott Lowe, who have strong records of discovering innovative treatments and targets for cancer. ORIC has assembled a team of highly-experienced scientists who are executing multiple drug discovery strategies targeting the mechanisms that allow tumors to become resistant to current therapies. In addition, the scientific team has unparalleled access to the operational expertise of advisors who have devoted their careers to oncology drug development. Finally, the Company is supported by investors with extensive experience in both drug development and the financing of life science companies.
ORIC Pharmaceuticals is headquartered in South San Francisco, California. For more information, please visit the Company’s website at http://www.oricpharma.com.
« back to news page
ORIC Pharmaceuticals Adds Richard Heyman, Ph.D., Former CEO of Aragon and Seragon, to its Board of Directors
March 09, 2015
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Heyman, Ph.D. will be joining its Board of Directors. Dr. Heyman was most recently CEO of Seragon Pharmaceuticals and, prior to that, CEO of Aragon Pharmaceuticals.
“I’ve had the pleasure of working with Rich Heyman on Aragon and Seragon, and he was an excellent leader with a strong sense of efficient drug development,” said Peter Svennilson, ORIC’s acting chief executive officer, referring to his time as Board Chairman of Aragon Pharmaceuticals and Seragon Pharmaceuticals. “He is very familiar with the basic science and clinical setting for hormone-resistant cancers and that will prove all the more helpful in shaping the strategic path of ORIC. His operational experience will be an invaluable asset to the Company.”
“ORIC has established an exceptional team focused on its greater mission,” said Dr. Heyman. “It will be an exciting period of growth and exploration for the Company as it establishes its discovery platform and selects its clinical programs.”
Dr. Heyman is a biopharmaceutical executive with over 25 years in the industry. Most recently he served as CEO of Seragon Pharmaceuticals, a company focused on the development of drugs targeting hormone dependent cancers that was acquired by the Roche group. He was also co-founder and CEO of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson in 2013. Previously, he co-founded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases which was acquired by Exelixis in 2004. Prior to X-Ceptor, he was Vice President of Research at Ligand Pharmaceuticals, where he led the development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the Board of Directors for BIOCOM, Organovo Inc., The Jenna Druck Center, and is a member of the Therapeutic Advisory Board for aTyr Pharma.
About ORIC Pharmaceuticals
ORIC is a privately-held pharmaceutical company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to these drugs. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.
ORIC was founded by two world-class experts in oncology, Dr. Charles Sawyers and Dr. Scott Lowe, who have strong records of discovering innovative treatments and targets for cancer. ORIC has assembled a team of highly-experienced scientists who are executing multiple drug discovery strategies targeting the mechanisms that allow tumors to become resistant to current therapies. In addition, the scientific team has unparalleled access to the operational expertise of advisors who have devoted their careers to oncology drug development. Finally, the Company is supported by investors with extensive experience in both drug development and the financing of life science companies.
ORIC Pharmaceuticals is headquartered in South San Francisco, California. For more information, please visit the Company’s website at http://www.oricpharma.com.
« back to news page